FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012282709> ?p ?o ?g. }

• W2012282709 endingPage "e11198" @default.
• W2012282709 startingPage "e11198" @default.
• W2012282709 abstract "Ovarian cancer is one of the most lethal types of female malignancy. Although most patients are initially responsive to platinum-based chemotherapy, almost all develop recurrent chemoresistant tumors and succumb to their diseases. Elucidating the pathogenesis underlying drug resistance is fundamental to the development of new therapeutics, leading to improved clinical outcomes in these patients.We compared the proteomes of paired primary and recurrent post-chemotherapy ovarian high-grade serous carcinomas from nine ovarian cancer patients using CIEF/Nano-RPLC coupled with ESI-Tandem MS. As compared to their primary tumors, more than half of the recurrent tumors expressed higher levels of several proteins including CP, FN1, SYK, CD97, AIF1, WNK1, SERPINA3, APOD, URP2, STAT5B and RELA (NF-kappaB p65), which were also validated by quantitative RT-PCR. Based on shRNA screening for the upregulated genes in in vitro carboplatin-resistant cells, we found that simultaneous knockdown of RELA and STAT5B was most effective in sensitizing tumor cells for carboplatin treatment. Similarly, the NF-kappaB inhibitor, BMS-345541, and the STAT5 inhibitor, Dasatinib, significantly enhanced cell sensitivity to carboplatin. Moreover, both RELA and STAT5 are known to bind to the promoter region of Bcl-X, regulating its promoter activity. In this regard, augmented Bcl-xL expression was detected in carboplatin-resistant cells. Combined ectopic expression of RELA and STAT5B enhanced Bcl-xL promoter activity while treatment with BMS-345541 and Dasatinib decreased it. Chromatin immunoprecipitation of the Bcl-X promoter region using a STAT5 antibody showed induction of RELA and STAT5 DNA-binding segments both in naïve cells treated with a high concentration of carboplatin as well as in carboplatin-resistant cells.Proteomic analysis identified RELA and STAT5 as two major proteins associated with carboplatin resistance in ovarian tumors. Our results further showed that NF-kappaB and STAT5 inhibitor could sensitize carboplatin-resistant cells and suggest that such inhibitors can be used to benefit patients with carboplatin-resistant recurrent ovarian cancer." @default.
• W2012282709 created "2016-06-24" @default.
• W2012282709 creator A5008100062 @default.
• W2012282709 creator A5012541202 @default.
• W2012282709 creator A5014887786 @default.
• W2012282709 creator A5016163101 @default.
• W2012282709 creator A5019250137 @default.
• W2012282709 creator A5021497635 @default.
• W2012282709 creator A5029740538 @default.
• W2012282709 creator A5030258060 @default.
• W2012282709 creator A5042253638 @default.
• W2012282709 creator A5044423965 @default.
• W2012282709 creator A5050257402 @default.
• W2012282709 creator A5064270578 @default.
• W2012282709 creator A5078288814 @default.
• W2012282709 date "2010-06-18" @default.
• W2012282709 modified "2023-10-05" @default.
• W2012282709 title "Oncoproteomic Analysis Reveals Co-Upregulation of RELA and STAT5 in Carboplatin Resistant Ovarian Carcinoma" @default.
• W2012282709 cites W1566853467 @default.
• W2012282709 cites W1970957241 @default.
• W2012282709 cites W1982852897 @default.
• W2012282709 cites W1992396964 @default.
• W2012282709 cites W2005453082 @default.
• W2012282709 cites W2019110880 @default.
• W2012282709 cites W2019865561 @default.
• W2012282709 cites W2022467034 @default.
• W2012282709 cites W2027599519 @default.
• W2012282709 cites W2062921699 @default.
• W2012282709 cites W2083394182 @default.
• W2012282709 cites W2083778754 @default.
• W2012282709 cites W2086753834 @default.
• W2012282709 cites W2098226360 @default.
• W2012282709 cites W2099356955 @default.
• W2012282709 cites W2101995865 @default.
• W2012282709 cites W2103762288 @default.
• W2012282709 cites W2104668641 @default.
• W2012282709 cites W2115413209 @default.
• W2012282709 cites W2115732428 @default.
• W2012282709 cites W2121686752 @default.
• W2012282709 cites W2122734862 @default.
• W2012282709 cites W2127281537 @default.
• W2012282709 cites W2133215155 @default.
• W2012282709 cites W2134994441 @default.
• W2012282709 cites W2138782161 @default.
• W2012282709 cites W2147921405 @default.
• W2012282709 cites W2152392253 @default.
• W2012282709 cites W2160527918 @default.
• W2012282709 cites W2166350458 @default.
• W2012282709 cites W2224782492 @default.
• W2012282709 cites W2318698183 @default.
• W2012282709 cites W4212835986 @default.
• W2012282709 doi "https://doi.org/10.1371/journal.pone.0011198" @default.
• W2012282709 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2887843" @default.
• W2012282709 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20585448" @default.
• W2012282709 hasPublicationYear "2010" @default.
• W2012282709 type Work @default.
• W2012282709 sameAs 2012282709 @default.
• W2012282709 citedByCount "77" @default.
• W2012282709 countsByYear W20122827092012 @default.
• W2012282709 countsByYear W20122827092013 @default.
• W2012282709 countsByYear W20122827092014 @default.
• W2012282709 countsByYear W20122827092015 @default.
• W2012282709 countsByYear W20122827092016 @default.
• W2012282709 countsByYear W20122827092017 @default.
• W2012282709 countsByYear W20122827092018 @default.
• W2012282709 countsByYear W20122827092019 @default.
• W2012282709 countsByYear W20122827092020 @default.
• W2012282709 countsByYear W20122827092021 @default.
• W2012282709 countsByYear W20122827092022 @default.
• W2012282709 countsByYear W20122827092023 @default.
• W2012282709 crossrefType "journal-article" @default.
• W2012282709 hasAuthorship W2012282709A5008100062 @default.
• W2012282709 hasAuthorship W2012282709A5012541202 @default.
• W2012282709 hasAuthorship W2012282709A5014887786 @default.
• W2012282709 hasAuthorship W2012282709A5016163101 @default.
• W2012282709 hasAuthorship W2012282709A5019250137 @default.
• W2012282709 hasAuthorship W2012282709A5021497635 @default.
• W2012282709 hasAuthorship W2012282709A5029740538 @default.
• W2012282709 hasAuthorship W2012282709A5030258060 @default.
• W2012282709 hasAuthorship W2012282709A5042253638 @default.
• W2012282709 hasAuthorship W2012282709A5044423965 @default.
• W2012282709 hasAuthorship W2012282709A5050257402 @default.
• W2012282709 hasAuthorship W2012282709A5064270578 @default.
• W2012282709 hasAuthorship W2012282709A5078288814 @default.
• W2012282709 hasBestOaLocation W20122827091 @default.
• W2012282709 hasConcept C104317684 @default.
• W2012282709 hasConcept C121608353 @default.
• W2012282709 hasConcept C126322002 @default.
• W2012282709 hasConcept C127561419 @default.
• W2012282709 hasConcept C153911025 @default.
• W2012282709 hasConcept C173396325 @default.
• W2012282709 hasConcept C2776694085 @default.
• W2012282709 hasConcept C2778239845 @default.
• W2012282709 hasConcept C2780427987 @default.
• W2012282709 hasConcept C2781451048 @default.
• W2012282709 hasConcept C3019054536 @default.
• W2012282709 hasConcept C502942594 @default.
• W2012282709 hasConcept C54355233 @default.

• next